Physician profile
Robert Michael Weaver
NPI 1588608509
$734.39
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $290 · 2022: $21.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $263.97 | 2019-2020 | |
| Amarin Pharma, INC. | $141.40 | 2019-2020 | |
| Pfizer INC. | $64.14 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.86 | 2020 | |
| Lilly USA, LLC | $36.21 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.28 | 2019 | |
| Allergan, INC. | $27.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $23.90 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $21.29 | 2022 | |
| Sanofi Pasteur INC. | $18.53 | 2019 | |
| Shire North American Group INC | $16.38 | 2019 | |
| Circassia INC. | $14.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2019 | |
| Genentech USA, INC. | $13.52 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.